Evidence map›Paper›PMID 36591248›Full record

ArticleFrontiers in immunology2022

A new framework for host-pathogen interaction research.

Hong Yu, Li Li, Anthony Huffman, John Beverley, Junguk Hur, Eric Merrell, Hsin-Hui Huang, Yang Wang, Yingtong Liu, Edison Ong and 17 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Hong YuDepartment of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital and National Health Commission (NHC) Key Laboratory of Immunological Diseases, People's Hospital of Guizhou Province, Guiyang, Guizhou, China.
Li LiDepartment of Genetics, Harvard Medical School, Boston, MA, United States.
Anthony HuffmanUniversity of Michigan Medical School, Ann Arbor, MI, United States.
John BeverleyDepartment of Philosophy, University at Buffalo, Buffalo, NY, United States.
Junguk HurDepartment of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, United States.
Eric MerrellDepartment of Philosophy, University at Buffalo, Buffalo, NY, United States.
Hsin-Hui HuangUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Yang WangDepartment of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital and National Health Commission (NHC) Key Laboratory of Immunological Diseases, People's Hospital of Guizhou Province, Guiyang, Guizhou, China.
Yingtong LiuUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Edison OngUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Liang ChengDepartment of Bioinformatics, Harbin Medical University, Harbin, Helongjian, China.
Tao ZengKey Laboratory of Systems Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
Jingsong ZhangKey Laboratory of Systems Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
Pengpai LiCenter of Intelligent Medicine, School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.
Zhiping LiuCenter of Intelligent Medicine, School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.
Zhigang WangDepartment of Biomedical Engineering, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Xiangyan ZhangDepartment of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital and National Health Commission (NHC) Key Laboratory of Immunological Diseases, People's Hospital of Guizhou Province, Guiyang, Guizhou, China.
Xianwei YeDepartment of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital and National Health Commission (NHC) Key Laboratory of Immunological Diseases, People's Hospital of Guizhou Province, Guiyang, Guizhou, China.
Samuel K HandelmanUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Jonathan SextonUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Kathryn EatonUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Gerry HigginsUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Gilbert S OmennUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Brian AtheyUniversity of Michigan Medical School, Ann Arbor, MI, United States.
Barry SmithDepartment of Philosophy, University at Buffalo, Buffalo, NY, United States.
Luonan ChenKey Laboratory of Systems Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
Yongqun HeUniversity of Michigan Medical School, Ann Arbor, MI, United States.

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Strategic Vision & Impact on Environmental HealthP30ES017885 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Dana Dolinoy · 2011 to 2026
$21.3M
Yersina perstis interactions with macrophagesP20GM113123 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI BRADLEY, DAVID S. · 2016 to 2025
$19.9M
National Library of Medicine Conference 2022T15LM012495 · NLM · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PETER L. ELKIN · 2017 to 2026
$4.3M
VIOLIN 2.0: Vaccine Information and Ontology LInked kNowledgebaseU24AI171008 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yongqun He, Junguk Hur · 2022 to 2026
$4.2M
University of Michigan Proteogenomics Data Analysis CenterU24CA210967 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, DHANASEKARAN, SARAVANA M · 2016 to 2020
$4.1M
Ontology-supported Integrative Analysis and Visualization of Vaccine-induced Pathways and NetworksUH2AI132931 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HE, YONGQUN, WU, GUANMING · 2019 to 2020
$437k
NCATS NIH HHS UL1 TR001412NCI NIH HHS U24 CA210967NIAID NIH HHS U24 AI171008NIAID NIH HHS UH2 AI132931NIEHS NIH HHS P30 ES017885NIGMS NIH HHS P20 GM113123NLM NIH HHS T15 LM012495
6 · The paper itself

Abstract

COVID-19 often manifests with different outcomes in different patients, highlighting the complexity of the host-pathogen interactions involved in manifestations of the disease at the molecular and cellular levels. In this paper, we propose a set of postulates and a framework for systematically understanding complex molecular host-pathogen interaction networks. Specifically, we first propose four host-pathogen interaction (HPI) postulates as the basis for understanding molecular and cellular host-pathogen interactions and their relations to disease outcomes. These four postulates cover the evolutionary dispositions involved in HPIs, the dynamic nature of HPI outcomes, roles that HPI components may occupy leading to such outcomes, and HPI checkpoints that are critical for specific disease outcomes. Based on these postulates, an HPI Postulate and Ontology (HPIPO) framework is proposed to apply interoperable ontologies to systematically model and represent various granular details and knowledge within the scope of the HPI postulates, in a way that will support AI-ready data standardization, sharing, integration, and analysis. As a demonstration, the HPI postulates and the HPIPO framework were applied to study COVID-19 with the Coronavirus Infectious Disease Ontology (CIDO), leading to a novel approach to rational design of drug/vaccine cocktails aimed at interrupting processes occurring at critical host-coronavirus interaction checkpoints. Furthermore, the host-coronavirus protein-protein interactions (PPIs) relevant to COVID-19 were predicted and evaluated based on prior knowledge of curated PPIs and domain-domain interactions, and how such studies can be further explored with the HPI postulates and the HPIPO framework is discussed.

Indexed as

COVID-19Host-Pathogen InteractionsHumansbioinformaticscoronavirus infectious disease ontology (CIDO)COVID-19COVID-19 cocktaildisease outcomehost-coronavirus interactionhost-pathogen interactionHPIPO framework

Identifiers

PMID36591248
PMCPMC9797517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.